The Latest

Promo Image

Ending Global Use of d4T: UNITAID to Tip Market to Safer Alternatives

On 11 June 2013, UNITAID announced in a press statement that it was committing USD $77 million to end of the use of the archaic HIV drug d4T (stavudine) and replace it with tenofovir which is a newer more effective alternative.1

Although d4T was wid...

Promo Image

d4T -- Time to Move On

The first conference of the Southern African Clinician's Society1 burst into life with a demonstration by the Treatment Action Campaign (TAC).

TAC were unequivocal that repurposing d4T at any dose is not an acceptable way to conquer cost concerns wi...

Promo Image

New Labeling for Zerit Capsules and Zerit for Oral Solution

On December 10, 2010, the FDA approved new labeling for Zerit capsules and Zerit for oral solution. The revisions to the Dosage and Administration, Warnings and Precautions, Adverse Reaction sections in both package inserts are outlined below.


Promo Image

South African Generic Drug Maker to Produce Country's First Generic Antiretroviral Drug

Aspen Pharmacare, southern Africa's largest generic drug manufacturer, yesterday announced that it will develop and produce the continent's first generic antiretroviral drug, called Aspen-Stavudine, South Africa's Mail & Guardian reports (Mail & Guar...

Promo Image

It's Time to Face the Zerit Problem

When I give lectures on how to manage the side effects of HIV medications, I am constantly reminded of how widespread the "sunken cheek" look has become. Many if not most of the men and women sitting in front of me show the severe facial wasting whic...

Promo Image

d4T and Lactic Acidosis With Neuromuscular Weakness: FDA Warning

The U.S. Food and Drug Administration emailed the following warning on March 1, 2002. The FDA also reported this information at the 9th Conference on Retroviruses and Opportunistic Infections on February 28 [abstract LB14].

[Comment: Patients sho...

Promo Image

FDA/Bristol Myers Squibb Issues Caution for HIV Combination Therapy With Zerit and Videx in Pregnant Women

FDA and Bristol Myers Squibb are warning health care professionals that pregnant women may be at increased risk of fatal lactic acidosis when prescribed the combination of the HIV drugs stavudine (Zerit) and didanosine (Videx or Videx EC) with other ...